Answers are grounded in this paper and cite their sources.
Observational analysis found neoantigen load and characteristics impact survival in early-stage NSCLC, suggesting immunotherapy insights.
Background Neoantigen-specific immune responses may help prevent cancer recurrence. We evaluated whether neoantigen load and/or properties could predict survival in early-stage non-small cell lung cancer (NSCLC). Methods Whole-exome sequencing (WES) data from 89 resected early-stage NSCLC patients were used to identify non-synonymous single-nucleotide variants (nsSNV) and to predict major histocompatibility complex class I neoantigens. Neoantigen load, differential aggretopicity index (DAI), neoantigen frequency (number of neoantigens per nsSNV) and neoantigen promiscuity (ability to bind multiple human leucocyte antigen (HLA) alleles) were assessed for association with time to recurrence (TTR) and recurrence-free survival (RFS). Results Higher neoantigen load was independently associated with longer TTR ( p = 0.028). A greater number of neoantigens with high DAI (≥ 10) were associated with improved TTR ( p = 0.008) whilst increased neoantigen promiscuity correlated with both longer TTR ( p = 0.007) and RFS ( p = 0.010). Conversely, elevated neoantigen frequency predicted a worse prognosis (TTR p = 0.016). Conclusions These data support a role for T cells in on-going immunosurveillance in resected NSCLC patients and suggest that both quality and quantity of neoantigens are important drivers of anti-cancer immunity and may inform future biomarker and immunotherapy development.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: